Destiny Pharma plc: Second positive Phase 1 trial data from XF-73
Primary objective achieved by both XF-73 concentrations
Brighton, United Kingdom - 28 January 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused
on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today
announces positive data and the non-irritant classification for its XF-73 nasal gel from the second Phase 1 safety clinical study
examining the drug's potential to cause irritation when administered topically.